Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Gloria S. Sivko"'
Autor:
Gloria S. Sivko, Lisa MacDonald, Marianne M. Stanford, Michelle Wright Valderas, Leeladhar Sammatur, Jon O. Rayner, Bradley J. Berger, Genevieve Weir, Rajkannan Rajagopalan
Publikováno v:
npj Vaccines, Vol 4, Iss 1, Pp 1-9 (2019)
NPJ Vaccines
NPJ Vaccines
Anthrax is a serious biological threat caused by pulmonary exposure to aerosolized spores of Bacillus anthracis. Biothrax® (anthrax vaccine adsorbed (AVA)) is the only Food and Drug Administration-licensed vaccine and requires five administrations o
Autor:
J.A. Hewitt, Gloria S. Sivko, Conrad P. Quinn, Jarad Schiffer, K.L. Taylor, Gregory V. Stark, M. VanRaden, Kevin P. Tordoff, E. Glaze, E.O. Nuzum
Publikováno v:
Vaccine. 34:6518-6528
Anthrax Vaccine Adsorbed (AVA, BioThrax) is approved by the US Food and Drug Administration for post-exposure prophylaxis (PEP) of anthrax in adults. The PEP schedule is 3 subcutaneous (SC) doses (0, 14 and 28 days), in conjunction with a 60 day cour
Autor:
M. Scot Roberts, Kevin P. Tordoff, Jianfeng Zhang, Bo H. Andersen, Matthew Duchars, Gloria S. Sivko, Christine Shoemaker, Vyjayanthi Krishnan, Tsungwei Feng, Gregory V. Stark
Publikováno v:
Clinical and Vaccine Immunology. 22:430-439
AdVAV is a replication-deficient adenovirus type 5-vectored vaccine expressing the 83-kDa protective antigen (PA83) fromBacillus anthracisthat is being developed for the prevention of disease caused by inhalation of aerosolizedB. anthracisspores. A n
Autor:
Daniel C. Sanford, Na Li, Vladimir Savransky, Gloria S. Sivko, Gregory V. Stark, Michael J. Lacy, Mario H. Skiadopoulos, Melicia Gainey, Boris Ionin, Jeffry D. Shearer
Publikováno v:
Vaccine. 35(37)
The anthrax vaccine candidate AV7909 is being developed as a next generation vaccine for a post-exposure prophylaxis (PEP) indication against anthrax. AV7909 consists of the Anthrax Vaccine Adsorbed (AVA, BioThrax®) bulk drug substance adjuvanted wi
Autor:
Ekaterina Vert-Wong, Suha Sari, Thomas L. Rudge, Robert J. Hopkins, Tina Guina, Frances M. Reid, Cris Howard, Gregory V. Stark, Jeffrey G. Smith, Boris Ionin, Gloria S. Sivko, Virginia Johnson, Kristin H. Clement, M. Lisa Swoboda, Gary S. Nabors, Mario H. Skiadopoulos, Brett Pleune, Alison Innes
Publikováno v:
Clinical and Vaccine Immunology. 20:1016-1026
Antimicrobials administered postexposure can reduce the incidence or progression of anthrax disease, but they do not protect against the disease resulting from the germination of spores that may remain in the body after cessation of the antimicrobial
Autor:
Gloria S. Sivko, J.A. Hewitt, M. VanRaden, Conrad P. Quinn, E.O. Nuzum, K.L. Taylor, Gregory V. Stark, Jarad Schiffer
Publikováno v:
Vaccine. 34(51)
Anthrax vaccine adsorbed (AVA, BioThrax) was recently approved by the Food and Drug Administration (FDA) for a post-exposure prophylaxis (PEP) indication in adults 18–65 years of age. The schedule is three doses administered subcutaneous (SC) at 2-
Publikováno v:
Journal of Applied Polymer Science. 99:3549-3564
Autor:
Leslie W. Baillie, Gloria S. Sivko, Jianfeng Zhang, Stanley Goldman, Tsungwei Feng, De-chu C. Tang, Edward Jex, Kent R. Van Kampen
Bacillus anthracis is the causative agent of anthrax, and its spores have been developed into lethal bioweapons. To mitigate an onslaught from airborne anthrax spores that are maliciously disseminated, it is of paramount importance to develop a rapid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc162dc1db34d424e910c81d4840f8b2
Autor:
Gloria S Sivko, Yvette S. Nout, Lawrence R Dearth, James W. DeWille, Kenneth W. Hinchcliff, Edward Jose-Cunilleras
Publikováno v:
American journal of veterinary research. 64(11)
Objective—To determine the effect of a single bout of exercise and increased substrate availability after exercise on gene expression and content of the glucose transporter-4 (GLUT-4) protein in equine skeletal muscle. Animals—6 healthy adult Tho
Publikováno v:
The FASEB Journal. 22:245-245